Introducing pentavalent vaccine in the EPI in India: A counsel for caution

The story of how pharmaceutical companies influenced scientists and official agencies like the World Health Organization (WHO) in the recent swine flu scare and the saga of the undeclared conflicts of interests of members of the WHO’s Strategic Advisory Group of Experts has set off alarm bells around the world. When trusted advisors are less than honest, the potential for harm is great, and the feeling of betrayal is poignant. A similar feeling of sadness and betrayal was evoked by the report of National Technical Advisory Group on Immunization (NTAGI) sub-committee on Haemophilus influenzae B (Hib) published recently. On December 14, 2009, the Health Secretary chaired a meeting to discuss the policy framework for vaccine preventable disease in the country. (Editorial)

Original Source